Biophytis GAAP EPS of -€9.48

Seeking AlphaOct 11 11:31 ET

6-K: Report of foreign private issuer (related to financial reporting)

SECJun 26 13:48 ET · Announcements

H.C. Wainwright Maintains BIOPHYTIS SPON ADR EACH REP 4000 ORD(POST SPLIT)(BPTSY.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsJun 20 12:32 ET · Ratings

Biophytis Announces An Exclusive License Agreement With Blanver For BIO101 (20-hydroxyecdysone) In Latin American, Biophytis Will Be Able To Receive Up To €108M Including An Upfront Payment And Further Additional Milestone Payments

BenzingaJun 20 04:58 ET

Express News | Biophytis Announces The Design Of Its Phase 2 OBA Clinical Study In Obesity With BIO101 (20-hydroxyecdysone)

BenzingaMay 14 03:36 ET

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

BenzingaApr 25 13:57 ET